← Leaderboards
Cassandra D Gipson-Reichardt
University Of Kentucky
$6,257,792
Attributed
$8,242,766
Total exposure
12
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.8M · FY2010–25$2M$1.5M$1M$500K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,242,766 · 12
By mechanism
R01$3,425,207 · 2
R33$1,854,763 · 1
R21$1,297,775 · 3
R00$836,438 · 1
R03$477,479 · 2
K99$262,108 · 1
Top collaborators
- William Walton Stoops5 shared
- Terry D Hinds3 shared
- M. Foster Olive1 shared
Most similar at University Of Kentucky
Same institution · by research overlap
- Bruce Jackson Hinds$2,220,404
- Lothar H Jennes$3,786,398
- William Walton Stoops$15,269,484
- Catherine Anne Martin$1,048,075
- Dustin Clark Lee$2,599,329
Others in their field
Top investigators on “Nucleus Accumbens”
- Eric J Nestler · Icahn School Of Medicine At Mount Sinai$48,768,834
- Yasmin L Hurd · Icahn School Of Medicine At Mount Sinai$23,420,464
- Peter W Kalivas · Ralph H Johnson Va Medical Center$21,520,620
- Marina Elizabeth Wolf · Oregon Health & Science University$19,421,692
- Scott J Russo · Icahn School Of Medicine At Mount Sinai$17,205,046
- Mary Kay Lobo · University Of Maryland Baltimore$15,138,110
Research focus
Nucleus AccumbensBrainSelf AdministrationNeurobiological MechanismSynaptic PlasticityNeuronsGlutamatesNeurobiologyPharmacotherapyPharmaceutical PreparationsNicotine DependenceCuesNovel TherapeuticsPublic HealthNicotineSynapsesSmokingBrain RegionDrug RewardRelapseN-MethylaspartateChemosensitizationRattusCells
Grant awards (35)
Neurobehavioral mechanisms underlying xylazine and fentanyl co-use and withdrawal$496,587
R01 · FY2025 · DA · contact PI
Neuroimmune and Cognitive Consequences of Nicotine Use in a Rodent Model of HIV: Implications for Anti-Retroviral Therapies$157,224
R03 · FY2025 · DA · contact PI
Glutamergic Mechanisms in Opioid and Cocaine Co-Use$630,599
R33 · FY2024 · DA · contact PI
Neurobehavioral mechanisms underlying xylazine and fentanyl co-use and withdrawal$502,057
R01 · FY2024 · DA · contact PI
Neuroimmune and Cognitive Consequences of Nicotine Use in a Rodent Model of HIV: Implications for Anti-Retroviral Therapies$166,375
R03 · FY2024 · DA · contact PI
Glutamergic Mechanisms in Opioid and Cocaine Co-Use$609,607
R33 · FY2023 · DA · contact PI
Neurobehavioral mechanisms underlying xylazine and fentanyl co-use and withdrawal$512,576
R01 · FY2023 · DA · contact PI
Neuroinflammatory and glutamatergic mechanisms of nicotine seeking$362,260
R01 · FY2023 · DA · contact PI
Contributions of Progestins Independently and Interactively with Contraceptive Estrogen to Nicotine Use$234,194
R21 · FY2023 · DA · contact PI
Neuroinflammatory and glutamatergic mechanisms of nicotine seeking$67,027
R01 · FY2023 · DA · contact PI
Neuroinflammatory and glutamatergic mechanisms of nicotine seeking$8,921
R01 · FY2023 · DA · contact PI
Glutamergic Mechanisms in Opioid and Cocaine Co-Use$614,557
R33 · FY2022 · DA · contact PI
Neuroinflammatory and glutamatergic mechanisms of nicotine seeking$362,260
R01 · FY2022 · DA · contact PI
Contributions of Progestins Independently and Interactively with Contraceptive Estrogen to Nicotine Use$200,673
R21 · FY2022 · DA · contact PI
Neuroinflammatory and glutamatergic mechanisms of nicotine seeking$368,291
R01 · FY2021 · DA · contact PI
Glutamergic Mechanisms in Opioid and Cocaine Co-Use$188,617
R21 · FY2021 · DA · contact PI
Neuroinflammatory and glutamatergic mechanisms of nicotine seeking$382,728
R01 · FY2020 · DA · contact PI
Glutamergic Mechanisms in Opioid and Cocaine Co-Use$213,600
R21 · FY2020 · DA · contact PI
Neuroinflammatory and glutamatergic mechanisms of nicotine seeking$362,500
R01 · FY2019 · DA · contact PI
Cholinergic modulation of glutamatergic signaling in nicotine addiction and relapse$201,749
R21 · FY2019 · DA
Glutamatergic mechanisms underlying nicotine addiction and relapse following nicotine reduction$58,592
R03 · FY2019 · DA · contact PI
Glutamatergic mechanisms underlying nicotine addiction and relapse following nicotine reduction$18,037
R03 · FY2019 · DA · contact PI
Cholinergic modulation of glutamatergic signaling in nicotine addiction and relapse$9,660
R21 · FY2019 · DA · contact PI
Cholinergic modulation of glutamatergic signaling in nicotine addiction and relapse$8,408
R21 · FY2019 · DA · contact PI
Contributions of Glial Glutamate Transport and NMDA Receptors in Nicotine Relapse$282,981
R00 · FY2018 · DA · contact PI
Cholinergic modulation of glutamatergic signaling in nicotine addiction and relapse$240,874
R21 · FY2018 · DA · contact PI
Glutamatergic mechanisms underlying nicotine addiction and relapse following nicotine reduction$77,251
R03 · FY2018 · DA · contact PI
Contributions of Glial Glutamate Transport and NMDA Receptors in Nicotine Relapse$283,409
R00 · FY2017 · DA · contact PI
Contributions of Glial Glutamate Transport and NMDA Receptors in Nicotine Relapse$248,999
R00 · FY2016 · DA · contact PI
Contributions of Glial Glutamate Transport and NMDA Receptors in Nicotine Relapse$21,049
R00 · FY2016 · DA · contact PI
Contributions of Glial Glutamate Transport and NMDA Receptors in Nicotine Relapse$131,054
K99 · FY2015 · DA · contact PI
Contributions of Glial Glutamate Transport and NMDA Receptors in Nicotine Relapse$131,054
K99 · FY2014 · DA · contact PI
Chronic Adaptations in Glutamatergic and Dopaminergic Signaling in Nicotine Abuse$21,746
F32 · FY2013 · DA · contact PI
Chronic Adaptations in Glutamatergic and Dopaminergic Signaling in Nicotine Abuse$49,214
F32 · FY2012 · DA · contact PI
A Translational Model of Mood-Based Drug Abuse$18,036
F31 · FY2010 · DA · contact PI